Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55)

被引:126
|
作者
Stoiber, H
Pinter, C
Siccardi, AG
Clivio, A
Dierich, MP
机构
[1] INST HYG,A-6020 INNSBRUCK,AUSTRIA
[2] LUDWIG BOLTZMANN INST AIDS FORSCH,A-6020 INNSBRUCK,AUSTRIA
[3] UNIV MILAN,DIPARTIMENTO BIOL & GENET SCI MED,LAB INTERDISCIPLINARE TECHNOL AVANZATE VIALBA,I-20157 MILAN,ITALY
[4] DIPARTIMENTO BIOL & TECHNOL SAN RAFFAELE,I-20132 MILAN,ITALY
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 1996年 / 183卷 / 01期
关键词
D O I
10.1084/jem.183.1.307
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Activation of the human complement system leads to complement deposition on human immunodeficiency virus (HIV) and HIV-infected cells without causing efficient complement-mediated lysis. Even in the presence of HIV-specific antibodies, only a few particles are destroyed, demonstrating that HIV is intrinsically resistant to human complement. Here we report that, in addition to decay accelerating factor (DAF) being partially responsible, human complement factor H (CFH), a humoral negative regulator of complement activation, is most critical for this resistance. In the presence of HIV-specific antibodies, sera devoid of CFH (total genetic deficiency or normal human serum depleted of CFH by affinity chromatography) lysed free virus and HIV-infected but not uninfected cells. In the presence of CFH, lysis of HIV was only obtained when binding of CFH to gp41 was inhibited by a monoclonal antibody against a main CFH-binding site in gp41. Since CFH is an abundant protein in serum, and high local concentration of CFH can be obtained at the surface of HIV as the result of specific interactions of CFH with the HIV envelope, it is proposed that the resistance of HIV and HIV-infected cells against complement-mediated lysis in vivo is dependent on DAF and CFH and can be overcome by suppressing this protection. Neutralization of HIV may be achieved by antibodies against DAF and, more importantly, antibodies against CFH-binding sites on HIV envelope proteins.
引用
收藏
页码:307 / 310
页数:4
相关论文
共 50 条
  • [21] Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack
    vanDenderen, BJW
    Pearse, MJ
    Katerelos, M
    Nottle, MB
    Du, ZT
    Aminian, A
    Adam, WR
    ShenoyScaria, A
    Lublin, DM
    Shinkel, TA
    dApice, AJF
    TRANSPLANTATION, 1996, 61 (04) : 582 - 588
  • [22] Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55)
    Harris, CL
    Abbott, RJM
    Smith, RA
    Morgan, BP
    Lea, SM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (04) : 2569 - 2578
  • [23] Sodium butyrate blocks cytokine-induced decay-accelerating factor (DAF;CD55) expression in human colon cancer cells.
    Andoh, A
    Shimada, M
    Fujiyama, Y
    Bamba, T
    GASTROENTEROLOGY, 2000, 118 (04) : A271 - A271
  • [24] Reduction in erythrocyte complement receptor 1 (CR1,CD35) and decay accelerating factor (DAF,CD55) during normal pregnancy
    Imrie, HJ
    McGonigle, TP
    Liu, DTY
    Jones, DRE
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1996, 31 (03) : 221 - 227
  • [25] TEST FOR ABILITY OF DECAY-ACCELERATING FACTOR (DAF, CD55) AND CD59 TO ALLEVIATE COMPLEMENT-MEDIATED DAMAGE OF XENO-ERYTHROCYTES
    MIYAGAWA, S
    SHIRAKURA, R
    MATSUMIYA, G
    NAKATA, S
    MATSUDA, H
    HATANAKA, M
    MATSUMOTO, M
    KITAMURA, H
    SEYA, T
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1993, 38 (01) : 37 - 44
  • [26] Cytokine-stimulated release of decay-accelerating factor (DAF; CD55) from HT-29 human intestinal epithelial cells
    Nasu, J
    Mizuno, M
    Uesu, T
    Takeuchi, K
    Inaba, T
    Ohya, S
    Kawada, M
    Shimo, K
    Okada, H
    Fujita, T
    Tsuji, T
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1998, 113 (03): : 379 - 385
  • [27] Bee Venom Alleviates Atopic Dermatitis Symptoms through the Upregulation of Decay-Accelerating Factor (DAF/CD55)
    Kim, Yenny
    Lee, Youn-Woo
    Kim, Hangeun
    Chung, Dae Kyun
    TOXINS, 2019, 11 (05):
  • [28] The Stromal Overexpression of Decay Accelerating Factor (DAF/CD55) Correlates with Poor Clinical Outcome in Colorectal Cancer Patients
    Baek, Tae-Hwa
    Kim, Joo-Heon
    Park, Mee-Ja
    Lee, Hye-Kyung
    Son, Hyun-Jin
    Soon, Hyun-Ki
    Kim, Chang-Nam
    Ko, Che Myong
    Kang, Dong-Wook
    KOREAN JOURNAL OF PATHOLOGY, 2011, 45 (05) : 445 - 454
  • [29] EXPRESSION OF COMPLEMENT REGULATORY PROTEIN MCP (MEMBRANE COFACTOR PROTEIN, CD46) AND DAF (DECAY ACCELERATING FACTOR, CD55) WITH HIV-INFECTION INVITRO
    JARVIS, JN
    TAYLOR, H
    LONG, PM
    GUTTA, V
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 97 - 97
  • [30] Nitric oxide induces segregation of decay accelerating factor (DAF or CD55) from the membrane lipid-rafts and its internalization in human endometrial cells
    Banadakoppa, Manu
    Goluszko, Pawel
    Liebenthal, Daniel
    Yallampalli, Chandra
    CELL BIOLOGY INTERNATIONAL, 2012, 36 (10) : 901 - 907